Citius Pharmaceuticals, Inc.

On December 2, 2025, we approved and entered into an amendment (the “Pagoda Note Amendment”) to our existing unsecured promissory note with Pagoda. The original note provided for aggregate principal of $1,000,000, bore interest at a per annum rate of 15.00% compounded monthly (or such lesser rate as the maximum permitted by applicable law), and was scheduled to mature on December 2, 2025. Pursuant to the Pagoda Note Amendment, we extended the maturity date to January 2, 2026. In consideration for the extension, we issued to Pagoda a warrant to purchase 75,000 shares of our common stock. The warrant has a five-year term commencing on the date of issuance and an exercise price equal to the closing price of our common stock on Nasdaq on the date of issuance, which was $1.26 per share.

On December 10, 2025, in connection with a common stock transaction effected by Citius Oncology, we amended the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 (the “Note”), issued by Citius Oncology to us to provide that the maturity of the Note would be the date at which Citius Oncology has closed a series of capital raises that in the aggregate provide gross proceeds of at least $50 million through the issuance of debt or equity securities or the royalty-backed monetization of LYMPHIR. All other terms of the Note remain the same.

On December 23, 2025, we extended the term of the Amended and Restated Employment Agreement between us and Myron Holubiak for an additional 12 months until October 31, 2026, effective as of October 31, 2025.